Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,191
archived clinical trials in
Constipation

Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in Miami, Florida
mi
from
Miami, FL
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in Miami, Florida
mi
from
Miami, FL
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in St. Augustine, FL
mi
from
Saint Augustine, FL
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in St. Augustine, FL
mi
from
Saint Augustine, FL
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in New York, New York
mi
from
New York, NY
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in New York, New York
mi
from
New York, NY
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in North Carolina
mi
from
Asheville, NC
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in North Carolina
mi
from
Asheville, NC
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in Dothan, Alabama
mi
from
Dothan, AL
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in Dothan, Alabama
mi
from
Dothan, AL
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in Lauderdale Lakes, FL
mi
from
Lauderdale Lakes, FL
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in Lauderdale Lakes, FL
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in Maitland, FL
mi
from
Maitland, FL
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in Maitland, FL
mi
from
Maitland, FL
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in Atlanta, GA
mi
from
Atlanta, GA
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in Atlanta, GA
mi
from
Atlanta, GA
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in Minneapolis, MN
mi
from
Minneapolis, MN
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated:  12/31/1969
One (1) Location in Greenville, SC
mi
from
Greenville, SC
Fecal Calprotectin Collection Protocol
CALFE Stool Sample Collection Protocol
Status: Enrolling
Updated: 12/31/1969
One (1) Location in Greenville, SC
mi
from
Greenville, SC
Click here to add this to my saved trials
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation
Status: Enrolling
Updated:  12/31/1969
MJHS Institute for Innovation in Palliative Care
mi
from
New York, NY
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation
Status: Enrolling
Updated: 12/31/1969
MJHS Institute for Innovation in Palliative Care
mi
from
New York, NY
Click here to add this to my saved trials
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation
Status: Enrolling
Updated:  12/31/1969
Hospice of Henderson County, Inc
mi
from
Flat Rock, NC
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation
Status: Enrolling
Updated: 12/31/1969
Hospice of Henderson County, Inc
mi
from
Flat Rock, NC
Click here to add this to my saved trials
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation
Status: Enrolling
Updated:  12/31/1969
Hospice of the Western Reserve
mi
from
Cleveland, OH
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation
Status: Enrolling
Updated: 12/31/1969
Hospice of the Western Reserve
mi
from
Cleveland, OH
Click here to add this to my saved trials
Computer-based Prescription Opioid Abuse Prevention for Adolescents
Computer-based Prescription Opioid Abuse Prevention for Adolescents
Status: Enrolling
Updated:  12/31/1969
Center for Technology and Behavioral Health
mi
from
Lebanon, NH
Computer-based Prescription Opioid Abuse Prevention for Adolescents
Computer-based Prescription Opioid Abuse Prevention for Adolescents
Status: Enrolling
Updated: 12/31/1969
Center for Technology and Behavioral Health
mi
from
Lebanon, NH
Click here to add this to my saved trials
ISE to Support Constipation Management
Interactive Spaced Education Game to Support Constipation Management in Pediatric Primary Care
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
ISE to Support Constipation Management
Interactive Spaced Education Game to Support Constipation Management in Pediatric Primary Care
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated:  12/31/1969
Colon and Rectal Clinic of Orlando
mi
from
Orlando, FL
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated: 12/31/1969
Colon and Rectal Clinic of Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated:  12/31/1969
Lahey Clinic
mi
from
Burlington, MA
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated: 12/31/1969
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated:  12/31/1969
Colon and Rectal Surgery Associates, Ltd
mi
from
Minneapolis, MN
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated: 12/31/1969
Colon and Rectal Surgery Associates, Ltd
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated:  12/31/1969
Medical University of Ohio, Department of Surgery
mi
from
Toledo, OH
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated: 12/31/1969
Medical University of Ohio, Department of Surgery
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated:  12/31/1969
Portland Medical Center
mi
from
Portland, OR
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)
Status: Enrolling
Updated: 12/31/1969
Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects With Opioid-Induced Constipation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pasadena, CA
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects With Opioid-Induced Constipation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Associates
mi
from
Huntsville, AL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Associates
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Elite Clinical Studies
mi
from
Phoenix, AZ
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Elite Clinical Studies
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Adobe Clinical Research, LLC
mi
from
Tucson, AZ
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Adobe Clinical Research, LLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Arkansas Gastroenterology
mi
from
North Little Rock, AR
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Arkansas Gastroenterology
mi
from
North Little Rock, AR
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
GW Research Inc,
mi
from
Chula Vista, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
GW Research Inc,
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Kindred Medical Institute For Clinical Trials, LLC
mi
from
Corona, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Kindred Medical Institute For Clinical Trials, LLC
mi
from
Corona, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Diagnamics Inc.
mi
from
Encinitas, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Diagnamics Inc.
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
MD Studies, Inc.
mi
from
Fountain Valley, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
MD Studies, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Paragon Rx Clinical, Inc. - Garden Grove
mi
from
Garden Grove, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Paragon Rx Clinical, Inc. - Garden Grove
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Facey Medical Foundation
mi
from
Mission Hills, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Facey Medical Foundation
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Providence Clinical Research
mi
from
North Hollywood, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Providence Clinical Research
mi
from
North Hollywood, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Precision Research Institute, LLC
mi
from
San Diego, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Precision Research Institute, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Paragon Rx Clinical, Inc.- Santa Ana
mi
from
Santa Ana, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Paragon Rx Clinical, Inc.- Santa Ana
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
St. Joseph Heritage Healthcare
mi
from
Yorba Linda, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
St. Joseph Heritage Healthcare
mi
from
Yorba Linda, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Connecticut Clinical Research Institute
mi
from
Bristol, CT
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Connecticut Clinical Research Institute
mi
from
Bristol, CT
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Chase Medical Research, LLC
mi
from
Waterbury, CT
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Palmetto Research
mi
from
Hialeah, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Palmetto Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Nature Coast Clinical Research
mi
from
Inverness, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Nature Coast Clinical Research
mi
from
Inverness, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
The Chappel Group Research
mi
from
Kissimmee, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
The Chappel Group Research
mi
from
Kissimmee, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
San Marcus Research Clinic
mi
from
Miami Lakes, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
San Marcus Research Clinic
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Ocean Blue Medical Research Center, Inc.
mi
from
Miami Springs, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Ocean Blue Medical Research Center, Inc.
mi
from
Miami Springs, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Jesscan Medical Research
mi
from
Miami, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Jesscan Medical Research
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Well Pharma Medical Research Corporation
mi
from
Miami, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Well Pharma Medical Research Corporation
mi
from
Miami, FL
Click here to add this to my saved trials